Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

ClinicalTrials.gov ID: NCT02542293

Public ClinicalTrials.gov record NCT02542293. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 18, 2026, 11:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC.

Study identification

NCT ID: NCT02542293
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: AstraZeneca; Industry
Enrollment: 953 participants

Conditions and interventions

Conditions

Non Small Cell Lung Carcinoma NSCLC

Interventions

Biological · Drug

Eligibility (public fields only)

Age range: 18 Years to 130 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2, 2015
Primary completion: Sep 20, 2020
Completion: Dec 30, 2026
Last update posted: Aug 5, 2026

2015 – 2026

United States locations

U.S. sites: 15
U.S. states: 8
U.S. cities: 15

Facility	City	State	ZIP	Site status
Research Site	Anaheim	California	92801	—
Research Site	San Diego	California	92123	—
Research Site	Santa Rosa	California	95403	—
Research Site	Louisville	Kentucky	40202	—
Research Site	Florham Park	New Jersey	07932	—
Research Site	Albuquerque	New Mexico	87102	—
Research Site	East Setauket	New York	11733	—
Research Site	Fresh Meadows	New York	11366	—
Research Site	Poughkeepsie	New York	12601	—
Research Site	Stony Brook	New York	11794	—
Research Site	Canton	Ohio	44710	—
Research Site	Columbus	Ohio	43219	—
Research Site	Zanesville	Ohio	43701	—
Research Site	Pittsburgh	Pennsylvania	15212	—
Research Site	Houston	Texas	77090	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 195 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02542293, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 5, 2026 · Synced Sep 18, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02542293 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →